165 related articles for article (PubMed ID: 38114128)
1. [Expert consensus on core indicators for lifecycle value assessment of Chinese patent medicine].
Yu YN; Liu J; Li B; Dang HX
Zhongguo Zhong Yao Za Zhi; 2023 Oct; 48(19):5389-5396. PubMed ID: 38114128
[TBL] [Abstract][Full Text] [Related]
2. [Guidelines for post-marketing research on clinical effectiveness of Chinese patent medicines].
Wang ZF; Xie YM; Tang JY; Zhang JH; Sun X; Yang ZQ
Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(3):842-848. PubMed ID: 38621888
[TBL] [Abstract][Full Text] [Related]
3. [Expert consensus on prescription comment of Chinese traditional patent medicine for promoting the rational use of drugs in Beijing].
Jin R; Zhao KJ; Guo GM; Zhang B; Wang YG; Xue CM; Yang YH; Wang LX; Li GH; Tang JF; Nie LX; Zhang XL; Zhao TT; Zhang Y; Yan C; Yuan SZ; Sun LL; Feng XZ; Yan D;
Zhongguo Zhong Yao Za Zhi; 2018 Mar; 43(5):1049-1053. PubMed ID: 29676107
[TBL] [Abstract][Full Text] [Related]
4. [Manual for the clinical experts consensus of Chinese patent medicine].
Fang SN; Guo YB; Liu JP; Liao X; Zhang XX; Mo M; Chen W
Zhongguo Zhong Yao Za Zhi; 2018 Dec; 43(24):4786-4791. PubMed ID: 30717520
[TBL] [Abstract][Full Text] [Related]
5. [Thoughts on post-marketing evaluation of classical Chinese patent medicines based on clinical value].
Song Z; Wang ZF; Wu Y; Xie YM; Yang YF; Xu Y
Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):1988-1993. PubMed ID: 33982509
[TBL] [Abstract][Full Text] [Related]
6. [Pre-searching during formulation of expert consensus on clinical application of Chinese patent medicines:Yanshen Jianwei Capsules as example].
Feng X; Duan XJ; Sun JW; Guo YB
Zhongguo Zhong Yao Za Zhi; 2021 Aug; 46(16):4287-4292. PubMed ID: 34467743
[TBL] [Abstract][Full Text] [Related]
7. [Expert consensus statement on Kangfu Xiaoyan Suppository in treatment of pelvic inflammatory in clinical practice].
Wang LX; Hou LH; Xie YM; Ma K; Sun SL; Jin Z; DU HL; Wang DM; Zhao H; Liu YF; Tang L; Shu KY; Zhang CZ; Shi W; Zhan SY; Liu JP; Chen W; Chen YL
Zhongguo Zhong Yao Za Zhi; 2019 Oct; 44(20):4350-4353. PubMed ID: 31872644
[TBL] [Abstract][Full Text] [Related]
8. [Report standards for clinical comprehensive evaluation of Chinese patent medicine].
Zhang Q; Wang ZF; Xie YM; Li YY; Wang LX; Liu H; Geng HJ; Cui X; Liu FM; Sun CQ; Wei RL; Zhang LD
Zhongguo Zhong Yao Za Zhi; 2021 Dec; 46(23):6062-6067. PubMed ID: 34951233
[TBL] [Abstract][Full Text] [Related]
9. [Clinical comprehensive evaluation of Chinese patent medicine based on EVIDEM].
Liao X; Dai ZQ; Wu X; Luo H; Zhao H; Zhang XX; Jia LL; Tang JY
Zhongguo Zhong Yao Za Zhi; 2022 May; 47(10):2833-2840. PubMed ID: 35718504
[TBL] [Abstract][Full Text] [Related]
10. [Clinical trials and evaluation of Chinese patent medicine for influenza].
Sheng XD; Chen Z; Ji ZC; Hu HY; Ou Y; Cao LJ; Guo LP; Zhang JH
Zhongguo Zhong Yao Za Zhi; 2022 May; 47(9):2338-2342. PubMed ID: 35531681
[TBL] [Abstract][Full Text] [Related]
11. [Clinical trials and evaluation of Chinese patent medicine for chronic obstructive pulmonary disease].
Feng CN; Hu HY; Ji ZC; Qiang XY; Chen Z; Ou Y; Cao LJ; Zhang JH
Zhongguo Zhong Yao Za Zhi; 2022 May; 47(9):2351-2357. PubMed ID: 35531683
[TBL] [Abstract][Full Text] [Related]
12. [Reporting standards for expert consensus on clinical practice of Chinese patent medicines of China Association of Chinese Medicine].
Mo M; Liao X; Zhang XX; Li B; Chen W; Zhao GZ; Guo YB
Zhongguo Zhong Yao Za Zhi; 2019 Jun; 44(12):2644-2651. PubMed ID: 31359735
[TBL] [Abstract][Full Text] [Related]
13. [Thoughts on foreign universal drug value evaluation tools for construction of Chinese patent medicine value evaluation tools].
Zhang Q; Wang ZF; Xie YM; Li LX
Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):1973-1979. PubMed ID: 33982507
[TBL] [Abstract][Full Text] [Related]
14. [Clinical comprehensive evaluation of Jinsang Sanjie Pills/Capsules in treatment of vocal nodule/polyp of vocal cord].
Hu J; Zhou TT; Ruan Y; Liao X
Zhongguo Zhong Yao Za Zhi; 2023 Dec; 48(23):6278-6284. PubMed ID: 38211984
[TBL] [Abstract][Full Text] [Related]
15. [Discussion on issues related to clinical experts consensus of Chinese patent medicine].
Fang SN; Sun SL; Guo YB; Liao X; Liu JP; Chen W
Zhongguo Zhong Yao Za Zhi; 2018 Dec; 43(24):4792-4795. PubMed ID: 30717521
[TBL] [Abstract][Full Text] [Related]
16. [Experts consensus statement on Xiyanping Injection in clinical practice(children)].
Wang ZF; Rong P; Ma R; Xie YM; Ding Y; Wang XF; Zhan SY; Li XH
Zhongguo Zhong Yao Za Zhi; 2019 Jul; 44(14):2932-2936. PubMed ID: 31602835
[TBL] [Abstract][Full Text] [Related]
17. [Experts consensus statement on Qilong Capsules in clinical practice].
Wang ZF; Xie YZ; Xie YM; Zhao DX; Wang MZ; Yu HQ; Cao XL; Li B
Zhongguo Zhong Yao Za Zhi; 2019 Dec; 44(24):5287-5290. PubMed ID: 32237370
[TBL] [Abstract][Full Text] [Related]
18. [Guideline for clinical comprehensive evaluation of Chinese patent medicine (2022 version)].
Yuan WA; Zhang JH; Liu JP; Yang ZQ; Cao JL; Liao X; Xi XY; Han M; Li WY; Qiu ZW; Feng SY; Guo YY; Cao LJ; Liao XH; Ai YL; Huang J; Jia LL; Su XF; Wu X; Dai ZQ; Guo JH; Lu BQ; Zhang XX; Tang JY
Zhongguo Zhong Yao Za Zhi; 2023 Jan; 48(1):256-264. PubMed ID: 36725278
[TBL] [Abstract][Full Text] [Related]
19. [Exploration and practice of post-marketing survival benefit evaluation of Chinese patent medicine for cancer].
Xu BW; Wu JY; Li J; Zhang Y; Cao LC; Zhang XX; Gao RK
Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):1980-1987. PubMed ID: 33982508
[TBL] [Abstract][Full Text] [Related]
20. [Guidelines for economic evaluation of post-marketing Chinese patent medicine].
Shi LW; Xie YM; Nie XY; Han S; Tian X; Wang ZF
Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1129-1136. PubMed ID: 38621920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
